MetaCap

AN2 Therapeutics (ANTX) vs Sol-Gel Technologies (SLGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed Sol-Gel Technologies (SLGL) over the past year, gaining 366.1% versus a gain of 50.5%. AN2 Therapeutics is the larger company by market cap ($192.8 million vs $180.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%SLGL+50.53%
+500%+235%-30%
Nov 21, 20251 yearNov 20, 2026
ANTX-67.01%SLGL-24.79%
+42%-30%-102%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus SLGL key metrics
MetricANTXSLGL
Share price$5.08$55.17
Market cap$192.75M$180.63M
1-day change-2.68%+2.02%
YTD return+345.61%+30.92%
1-year return+366.06%+50.53%
5-year return—-28.44%
EPS (TTM)$-0.91$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$19.39M
Revenue growth (YoY)—+68.04%
Net income (latest FY)$-35.17M$-6.13M
Operating margin—-38.88%
Net margin—-31.60%
52-week high$7.19$97.97
52-week low$1.00$34.47
Distance from 52-week high-29.35%-43.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.17%+181.86%
Average volume289.29K47.38K
Shares outstanding37.94M3.27M
Employees2128
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed SLGL by 315.5 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Sol-Gel Technologies

SLGL stock →

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

ANTX vs SLGL FAQ

Which is bigger, AN2 Therapeutics or Sol-Gel Technologies?

AN2 Therapeutics (ANTX) is larger, with a market capitalization of $192.75M compared with $180.63M for Sol-Gel Technologies (SLGL).

Which stock has performed better over the past year, ANTX or SLGL?

ANTX returned +366.06% over the past 12 months, compared with +50.53% for SLGL (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and Sol-Gel Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons